ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

The Food and Drug Administration (FDA) recently approved a new, non-opioid (non-narcotic) prescription pill, suzetrigine (SUE ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

In 2016, the Care Act helped give funding to give pharmacies the chance to help create new drugs. A part of that research helped produce Journavx, which is a painkiller that’s been developed that ...

Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the urgent need ...

Consider that since December, Vertex Pharmaceuticals has earned approval for two brand-new medicines: Alyftrek and Journavx. The former is the biotech's latest cystic fibrosis (CF) medicine.